Ísrael - enska - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 10 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 15 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 2.5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 20 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 25 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 7.5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Bandaríkin - enska - NLM (National Library of Medicine)

apotex corp. - lenalidomide (unii: f0p408n6v4) (lenalidomide - unii:f0p408n6v4) - lenalidomide capsules in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (mm). lenalidomide capsules are indicated as maintenance therapy in adult patients with mm following autologous hematopoietic stem cell transplantation (auto-hsct). lenalidomide capsules are indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide capsules are indicated for the treatment of adult patients with mantle cell lymphoma (mcl) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. lenalidomide capsules in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (fl). lenalidomide capsules in combination with a rituximab product, is indicated for the

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 18.15 mg - capsule - excipient ingredients: microcrystalline cellulose; indigo blue; titanium dioxide; croscarmellose sodium; gelatin; purified talc; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.